This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bleeding Time Study With AZD6482, Clopidogrel and ASA

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: February 27, 2009
Last updated: August 18, 2009
Last verified: August 2009
The primary purpose of this study is to evaluate the effect of AZD6482 and clopidogrel on bleeding time when taken together with low-dose ASA.

Condition Intervention Phase
Antiplatelet Effect Drug: AZD6482 Drug: Clopidogrel Drug: ASA Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised, Open-label, Single-Centre, Phase I, Crossover Study to Evaluate the Effect of AZD6482, Compared With Clopidogrel, on Bleeding Time in Healthy Volunteers Receiving Low-Dose ASA

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Capillary Bleeding Time (CBT) [ Time Frame: Prior to first dose in each treatment period, on study day 6 and 7 in treatment period A and on study day 7 in treatment period B ]

Secondary Outcome Measures:
  • Effect on bleeding [ Time Frame: Prior to first dose in each treatment period, twice on study day 6 and three times on study day 7 in treatment period A and twice on study day 7 in treatment period B ]
  • Pharmacokinetics [ Time Frame: Prior to AZD6482 infusion and repeatedly during 6 hours after end of infusion ]
  • Safety variables (adverse events, blood pressure, pulse, ECG, safety lab) [ Time Frame: Repeatedly during the study ]

Estimated Enrollment: 28
Study Start Date: February 2009
Study Completion Date: July 2009
Arms Assigned Interventions
Experimental: 1
AZD6482 on top of ASA
Drug: AZD6482
Single intravenous infusion during a maximum of 5 hours
Drug: ASA
75 mg orally once daily during 7 days in each treatment arm
Other Name: Trombyl®
Active Comparator: 2
Clopidogrel on top of ASA
Drug: Clopidogrel
Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
Other Name: Plavix®
Drug: ASA
75 mg orally once daily during 7 days in each treatment arm
Other Name: Trombyl®


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI between 19.0 and 30.0 kg/m2, inclusive and body weight between 50.0 and 100.0 kg, inclusive
  • Provision of written informed consent

Exclusion Criteria:

  • Personal or family history of bleeding disorders, or reasonable suspicion of vascular malformations, including aneurysms.
  • Acute illness, surgical procedure or trauma from 2 weeks before pre-entry visit until the first baseline visit or clinically significant abnormalities in clinical chemistry, haematology, urinalysis or supine BP or pulse
  • Known impaired glucose tolerance, known galactose intolerance, total lactase deficiency or glucose-galactose malabsorption or known or suspected Gilbert's syndrome
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00853450

Research Site
Lund, Sweden
Sponsors and Collaborators
Study Director: Peter Held AstraZeneca Mölndal
Principal Investigator: Bo Fransson, MD AstraZeneca Clinical Pharmacology Unit, Lund
  More Information

Responsible Party: Peter Held, Medical Science Director, Early Thrombosis & Haemostasis, AstraZeneca Identifier: NCT00853450     History of Changes
Other Study ID Numbers: D1700C00004
EudraCT no. 2008-007030-21
Study First Received: February 27, 2009
Last Updated: August 18, 2009

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Fibrinolytic Agents
Fibrin Modulating Agents
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors processed this record on September 20, 2017